P&G reformulating to reduce 1,4-dioxane?
This article was originally published in The Rose Sheet
Executive Summary
According to the Campaign For Safe Cosmetics, Procter & Gamble will reformulate 18 of its Herbal Essences shampoos to reduce levels of trace contaminant 1,4-dioxane as part of an agreement with David Steinman, founder of the Green Patriot Working Group, who filed a notice of intent to sue under California's Proposition 65. Steinman's testing found that Herbal Essences shampoos had 1,4-dioxane levels of 24 parts per million (ppm), more than double the 10 ppm "actionable level" suggested by prior legal action in the state under the "landmark toxics law," group says. Campaign rep Lisa Archer says 1,4-dioxane - a probable human carcinogen, according to the Environmental Protection Agency - is "just the tip of the iceberg when it comes to problematic chemicals in personal-care products." While the Campaign applauds P&G's decision to address 1,4-dioxane, the organization maintains that "even more is needed to assure customers that P&G products are free of chemicals." P&G could not be reached for comment; however, the firm has noted in the past that settling suits filed under Prop 65 can be more economical than fighting them, even when a firm is not actually in violation (1"The Rose Sheet" Sept. 15, 2008
You may also be interested in...
Settling Prop 65 Suits Is Easier, Cheaper Than Fighting, Firms Say
It can be easier to settle suits filed under California's Proposition 65 than to fight them, even in cases where firms say they are not in violation
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.